$22.00
Price
$2.8B
Market Cap
61.1
P/E Ratio
-16.4
Forward P/E
$0.36
EPS (TTM)
—
Dividend Yield
$480M
Cash
$470M
Total Debt
127M
Shares Out
$16.10
$30.91
52-Week Range
Institutional Ownership of APELLIS PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for APELLIS PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2022-Q4 | |||||
| SELL | EXIT | — | — | $51.71 | |
| 2022-Q3 | |||||
| BUY | NEW | 932.4K | $64M | $61.09 | |
Insider Trading for APELLIS PHARMACEUTICALS INC
6 Months Insider Sentiment
Buy $0
Sell $200K
0
Buys
2
Sells
-200K
Net
7
Grants
Largest
$122K
Watson
$77K
Baumal
$13K
Watson
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 07, 2026 | David O. Watson | General Counsel | EXERCISE | 888 | $14.95 | $13K |
| Jan 05, 2026 | Caroline Baumal | Chief Medical Officer | SELL | 3.0K | $25.53 | $77K |
| Jan 01, 2026 | Stephanie Monaghan O'Brien | Director | GRANT | 8.0K | — | — |
| Jan 01, 2026 | Craig A Wheeler | Director | GRANT | 8.0K | — | — |
| Jan 01, 2026 | Alec Machiels | Director | GRANT | 8.0K | — | — |
| Jan 01, 2026 | Gerald Chan | Director | GRANT | 8.0K | — | — |
| Jan 01, 2026 | Keli Walbert | Director | GRANT | 8.0K | — | — |
| Jan 01, 2026 | Paul R. Fonteyne | Director | GRANT | 8.0K | — | — |
| Jan 01, 2026 | Sinclair A. Dunlop | Director | GRANT | 8.0K | — | — |
| Dec 16, 2025 | David O. Watson | General Counsel | SELL | 5.0K | $24.49 | $122K |